BioPlus Acquisition Corp.

BioPlus Acquisition Corp. (Nasdaq: BIOS) is a blank-check company formed to pursue a merger or acquisition in the healthcare and life sciences sector, with a focus on biotechnology and pharmaceutical opportunities. The SPAC completed its initial public offering in 2021 and remained in its target-search phase as of its Form 10-Q filing with the SEC on November 3, 2022. The filing, bearing accession number 0001193125-22-277012, reflects the company's continued operations as a development-stage entity pending a business combination. Sign up at SpacDesk for full filing history, deal timelines, and real-time data on BIOS and hundreds of other SPACs.